Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Lifted by MCF Advisors LLC

MCF Advisors LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 108.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 77 shares of the medical equipment provider’s stock after buying an additional 40 shares during the quarter. MCF Advisors LLC’s holdings in Intuitive Surgical were worth $26,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ISRG. International Assets Investment Management LLC grew its stake in Intuitive Surgical by 14.9% in the third quarter. International Assets Investment Management LLC now owns 2,116 shares of the medical equipment provider’s stock valued at $617,000 after purchasing an additional 275 shares in the last quarter. Arkadios Wealth Advisors grew its stake in Intuitive Surgical by 30.2% in the third quarter. Arkadios Wealth Advisors now owns 1,318 shares of the medical equipment provider’s stock valued at $385,000 after purchasing an additional 306 shares in the last quarter. Global Retirement Partners LLC grew its stake in Intuitive Surgical by 9.9% in the third quarter. Global Retirement Partners LLC now owns 1,852 shares of the medical equipment provider’s stock valued at $538,000 after purchasing an additional 167 shares in the last quarter. Flagship Harbor Advisors LLC boosted its stake in shares of Intuitive Surgical by 4.2% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 2,783 shares of the medical equipment provider’s stock worth $813,000 after acquiring an additional 113 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its stake in shares of Intuitive Surgical by 74.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 1,018 shares of the medical equipment provider’s stock worth $298,000 after acquiring an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other news, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Myriam Curet sold 4,318 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the sale, the executive vice president now directly owns 189 shares in the company, valued at approximately $69,958.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now owns 110 shares in the company, valued at $43,677.70. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock valued at $95,927,097 in the last quarter. Corporate insiders own 0.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ISRG. Stifel Nicolaus upped their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. BTIG Research upped their price target on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Company upped their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Finally, Piper Sandler upped their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Up 0.7 %

Intuitive Surgical stock opened at $368.93 on Tuesday. The business has a 50 day moving average price of $386.57 and a two-hundred day moving average price of $344.41. The stock has a market cap of $130.77 billion, a price-to-earnings ratio of 66.59, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.00 EPS. On average, analysts expect that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.